FAQs
What is the relationship between Beren and Mandos?
Mandos LLC is a subsidiary of Beren Therapeutics PBC. Mandos was founded when Beren acquired the adrabetadex asset in 2021 to serve as an externally facing arm of Beren that could publicly support the adrabetadex Expanded Access Program (EAP), engage with the NPC patient community, and interact with the FDA as the sponsor of adrabetadex. Mandos remains the sponsor of adrabetadex as a wholly owned subsidiary of Beren. Everyone who is involved with Mandos is a full-time Beren employee.
When was Beren founded?
Beren was founded in 2019.
Why did Beren operate in “stealth” mode through 2025?
We wanted to stay focused while we built the foundation and infrastructure to advance our biology and chemistry and the adrabetadex program – science, data, stakeholder engagement, and the operational capabilities to execute. Even with our stealth status, we've had targeted engagements with our communities to advance our science and our programs.
With the FDA’s acceptance of the adrabetadex NDA and a defined PDUFA date, it is an appropriate moment to introduce Beren publicly as a committed partner to the NPC community and the long-standing parent company of Mandos.
What is a Public Benefit Corporation?
A Public Benefit Corporation (PBC) is a for-profit corporate structure organized under Delaware Law. The key difference from a standard corporation is that a PBC specifies public benefit stakeholders in its charter and can consider those stakeholders’ interests alongside the company’s fiduciary duty to its stockholders when making decisions.
Beren will release more information about our unique operating model as a PublicBenefit Corporation at a later date.
Where did Beren’s science originate?
Beren’s science builds on decades of foundational biochemistry and Nobel‑recognized discoveries in cholesterol homeostasis (Brown and Goldstein) that established how disruptions in intracellular cholesterol movement drive diseases such as NPC. Recognizing that cyclodextrins as cyclic oligosaccharides with a hydrophilic exterior and hydrophobic cavity are uniquely suited to restore cellular cholesterol trafficking, Beren has built a platform to create novel, precisely derivatized cyclodextrins previously inaccessible for rational SAR.
What is the status of Beren’s lead product candidate?
Beren, through its subsidiary Mandos, is developing adrabetadex for the treatment of Niemann-Pick disease type C and has collaborated closely with the patient community over the past six years to progress the development of adrabetadex.
What is Beren doing in Niemann-Pick disease type C?
Beren’s most advanced program is the adrabetadex program for the treatment of infantile Niemann-Pick disease type C, which is managed by Beren’s wholly owned subsidiary Mandos. That program currently has a New Drug Application under review by the FDA, with a PDUFA date of August 17, 2026.
Have other questions? Reach out to us at contact@berentx.com.
